IR Banner

Press Releases

Date Title and Summary Additional Format
Mar 4, 2021
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
Data Analysis Supports Use of Predictive Enrichment Markers in Phase 2b OraGrowtH210 Trial AUSTIN, Texas , March 04, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that results of
PDF Version
Mar 2, 2021
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
AUSTIN, Texas , March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting, March 20 th -23 rd .
PDF Version
Feb 22, 2021
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
AUSTIN, Texas , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2020 financial results after market close on Tuesday, March 9, 2021 .
PDF Version
Feb 16, 2021
Lumos Pharma Announces Changes to its Board of Directors
Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience in rare diseases AUSTIN, Texas , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the
PDF Version
Email Alerts Subscription
Download Library
Print
Share
Search Investors